Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease
Background Parkinson's disease (PD) is histopathologically characterized by the loss of dopamine neurons in the substantia nigra pars compacta. The depletion of these neurons is thought to reduce the dopaminergic function of the nigrostriatal pathway, as well as the neural fibers that link the...
Saved in:
Published in | Movement disorders Vol. 30; no. 9; pp. 1229 - 1236 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.08.2015
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
Parkinson's disease (PD) is histopathologically characterized by the loss of dopamine neurons in the substantia nigra pars compacta. The depletion of these neurons is thought to reduce the dopaminergic function of the nigrostriatal pathway, as well as the neural fibers that link the substantia nigra to the striatum (putamen and caudate), causing a dysregulation in striatal activity that ultimately leads to lack of movement control. Based on diffusion tensor imaging, visualizing this pathway and measuring alterations of the fiber integrity remain challenging. The objectives were to 1) develop a diffusion tensor tractography protocol for reliably tracking the nigrostriatal fibers on multicenter data; 2) test whether the integrities measured by diffusion tensor imaging of the nigrostriatal fibers are abnormal in PD; and 3) test whether abnormal integrities of the nigrostriatal fibers in PD patients are associated with the severity of motor disability and putaminal dopamine binding ratios.
Methods
Diffusion tensor tractography was performed on 50 drug‐naïve PD patients and 27 healthy control subjects from the international multicenter Parkinson's Progression Marker Initiative.
Results
Tractography consistently detected the nigrostriatal fibers, yielding reliable diffusion measures. Fractional anisotropy, along with radial and axial diffusivity of the nigrostriatal tract, showed systematic abnormalities in patients. In addition, variations in fractional anisotropy and radial diffusivity of the nigrostriatal tract were associated with the degree of motor deficits in PD patients.
Conclusion
Taken together, the findings imply that the diffusion tensor imaging characteristic of the nigrostriatal tract is potentially an index for detecting and staging of early PD. © 2015 International Parkinson and Movement Disorder Society |
---|---|
Bibliography: | NIH - No. P41 EB015904 Covance Bristol-Myers Squibb GlaxoSmithKline Abbot Michael J. Fox Foundation for Parkinson's Research (MJFF) Pfizer GE Healthcare ark:/67375/WNG-200QN3BZ-G Merck Parkinson's Progression Marker Initiative (PPMI) Genentech F. Hoffman-La Roche, Ltd. MesoScale UCB istex:890A8E6D6523B73D0A125165664F04B4D8676277 ArticleID:MDS26251 Elan Corporation Biogen Idec Eli Lilly & Co. Lundbeck Avid Radiopharmaceuticals Full financial disclosures and author roles may be found in the online version of this article. The study was supported by the funding partners of the Parkinson's Progression Marker Initiative (PPMI) group. PPMI is sponsored by the Michael J. Fox Foundation for Parkinson's Research (MJFF) and is co‐funded by MJFF, Abbot, Avid Radiopharmaceuticals, Biogen Idec, Bristol‐Myers Squibb, Covance, Elan Corporation, Eli Lilly & Co., F. Hoffman‐La Roche, Ltd., GE Healthcare, Genentech, GlaxoSmithKline, Lundbeck, Merck, MesoScale, Pfizer and UCB. The study was also supported by an NIH grant (P41 EB015904). The statistical analysis was conducted by Dr. Norbert Schuff, PhD. 1,2 Dr. Yu Zhang has no disclosures to report. Ms. I‐Wei Wu has no disclosures to report. Mr. Shannon Buckley has no disclosures to report. Dr. Christopher S. Coffey has no disclosure to report. Dr. Eric Foster has no disclosures to report. Ms. Susan Mendick has no disclosures to report. Dr. John Seibyl has received research funding from Michael J. Fox Foundation for Parkinson's Research, consulting fees from GE Healthcare, Navidea Biopharmaceuticals, and Piramal Imaging. He has equity interest in Molecular Neuroimaging, LLC. Dr. Norbert Schuff receives research funding from Michael J. Fox Foundation for Parkinson's Research, National Institutes of Health, Department of Defense, and consulting honoraria from Eli Lilly. Relevant conflicts of interest/financial disclosures Funding agencies ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 The statistical analysis was conducted by Dr. Norbert Schuff, PhD1,2. |
ISSN: | 0885-3185 1531-8257 1531-8257 |
DOI: | 10.1002/mds.26251 |